NCT06000917 is a Phase 2 clinical trial of pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel in Breast Cancer, sponsored by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology.

What drugs are being tested in NCT06000917?

Interventions in NCT06000917: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel.

What condition does NCT06000917 study?

NCT06000917 studies Breast Cancer, Neoadjuvant.

Is NCT06000917 still recruiting?

NCT06000917 is currently recruiting now. Last updated 21 August 2023.

Last reviewed 2023-08-21 · How we verify

NCT06000917

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

Recruiting now Phase 2 Last updated 21 August 2023

What this trial tests

Phase 2 trial testing pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel in Breast Cancer in 62 participants. Currently enrolling.

Timeline

11 May 2023

Primary endpoint
11 May 2025

11 May 2028

Quick facts

Lead sponsor	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	62
Start date	11 May 2023
Primary completion	11 May 2025
Estimated completion	11 May 2028
Sites	2 locations across China

Drugs / interventions tested

pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel — full drug profile →

Conditions studied

Breast Cancer — all drugs for Breast Cancer →
Neoadjuvant — all drugs for Neoadjuvant →

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Who can join

Adults 18 to 75, female only, with Breast Cancer or Neoadjuvant. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Novel HER-2 Targeted Therapies in Breast Cancer.
Fernandes CL, Silva DJ, Mesquita A. · · 2023 · cited 9× · PMID 38201515 · DOI 10.3390/cancers16010087
Trend of albumin nanoparticles in oncology: a bibliometric analysis of research progress and prospects.
Liu Y, Li Y, Shen W, Li M, et al · · 2024 · cited 6× · PMID 39070787 · DOI 10.3389/fphar.2024.1409163

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other Union Hospital, Tongji Medical College, Huazhong University of Science and Technology trials

Trials by the same sponsor.

NCT07521124 — ABC Maintenance Therapy for AML · NA · not yet recruiting
NCT07497243 — X-ray Assisted Diagnostic System · not yet recruiting
NCT07520123 — Union-FAST: An Intelligent-Agent Intervention to Increase Antiviral Treatment Uptake in Diagnosed-but-Untreated Hepatiti · NA · not yet recruiting
NCT06970262 — FMT for Lung and Associated-organ Rescue Efficacy in ARDS Patients · NA · recruiting
NCT07509424 — Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Lo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06000917 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Last refreshed: 21 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06000917.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing